Contact
QR code for the current URL

Story Box-ID: 107215

Agennix AG Landsbergerstrasse 302 80687 München, Germany http://www.agennix.com
Contact Martin Brändle +49 89 85652693
Company logo of Agennix AG
Agennix AG

Präsentation weiterer Wirksamkeitsdaten aus der Phase-3-Zulassungsstudie SPARC mit Satraplatin

(PresseBox) (Martinsried, )
.
- Zeit bis zur Verschlimmerung der Schmerzen im Median: 66,1 Wochen für Satraplatin-Gruppe im Vergleich zu 22,3 Wochen für Kontroll-Gruppe
- Hazard Ratio: 3,27 (31% Pzkdhwudgxjycfqsig: 8,10-0,63; g
The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2024, All rights reserved

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.